Last reviewed · How we verify

NCT05899140: SoTiClin

Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial

Recruiting now Phase 4 Last updated 9 December 2024
What this trial tests

Phase 4 trial testing Clindamycin in Skin Infection in 100 participants. Currently enrolling.

Timeline
15 March 2024
Primary endpoint
29 March 2026
31 July 2026

Quick facts

Lead sponsorFrieder Schaumburg
PhasePhase 4
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment100
Start date15 March 2024
Primary completion29 March 2026
Estimated completion31 July 2026
Sites1 location across Sierra Leone

Drugs / interventions tested

Conditions studied

Sponsor

Frieder Schaumburg

Who can join

18 and older, any sex, with Skin Infection or Staphylococcal Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an exploratory study to evaluate the effect of adjunctive clindamycin in the treatment of skin and soft-tissue infections due to Staphylococcus aureus in patients from Sierra Leone. The study hypothesizes that clindamycin, when added to routine treatment, will lead to a more rapid clinical resolution and less frequent recurrences of infection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Clindamycin

Trials testing the same drug.

Other recruiting trials for Skin Infection

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05899140.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing